Canadian regulators have approved AstraZeneca's key new heart drug Brilinta, boosting prospects for a product whose future in North America is uncertain... more
AstraZeneca shares dive 5% or 156p to 2996.5p after US drug regulators refused to approve its potential new blockbuster heart medicine, Brilinta... more
AstraZeneca’s vandetanib pill may have failed last year as a lung cancer treatment, but it has now been submitted as a treatment for thyroid cancer... more
Shares in AstraZeneca plunge 40.5p to 3344.5p after US drug regulators ask for more time to decide whether to approve its potential new blockbuster heart medicine, Brilinta... more
Senior parliamentarians were accused of blocking the introduction of a Commons anti-bullying policy to stop sexual harassment and other abusive behaviour by MPs... more
Drugmaker SkyePharma sees its shares plunge 5% after pharmaceuticals giant Abbott Laboratories ends the deal to sell its asthma drug Flutiform in America... more
Drugs giant AstraZeneca was showing the rest of the top 100 companies a clean pair of heels, spurred on by recommendations from two of the City’s biggest players... more
Britons will have to wait for a pioneering line of defence against swine flu according to AstraZeneca, which admitted its H1N1 vaccine has been hit by delays
... more
Pharmaceuticals giant AstraZeneca received a boost when the US drug watchdog took the first steps to approve its $4.5 billion anti-psychotic medicine Seroquel for use by children... more
AstraZeneca has been told by the US Food and Drug Administration that its second biggest-selling drug should not be used as a major treatment for depression... more
Two years ago the fortunes of private-equity companies were riding high, but not any more. The credit crunch and subsequent stock market crash have made life difficult for the likes of 3i Group, which saw its shares slump to yet another new low today.... more
The big income funds, which look after our pensions and life assurance annuities, may have to face up to some lean stock-market pickings in 2009.... more
Health: Drug giants AstraZeneca and Pfizer have received a boost for their cholesterol-lowering medicines after a US report said they do not increase the risk of the neurological disorder known as Lou Gehrig's disease... more
Exclusive: After high-profile allegations this season, Charlton's manager is pleased the issue is now being addressed but says the authorities still have plenty of work to do
Afternoon:
8°c
